About

The National Health and Medical Research Council (NHMRC) has granted $2.49 million over five years to establish a Centre for Research Excellence (CRE) to improve health outcomes for children with cerebral palsy. 

The CRE will build an Australasian Cerebral Palsy Clinical Trials network combining leading research centres in five states of Australia and New Zealand to form an Australian Clinical Trials Alliance. Our network will conduct world standard, multisite, clinical trials to improve early detection and determine the best interventions and treatments for children with cerebral palsy.

The Centre for Research Excellence is being led by:

  • CIA Professor Roslyn Boyd, Queensland Cerebral Palsy & Rehabilitation Research Centre, The University of Queensland
  • CIB Professor Iona Novak, The Cerebral Palsy Alliance, The University of Sydney.
  • CIC Professor Euan Wallace, Hudson Institute of Medical Research, Monash University.
  • CID Professor Nadia Badawi, The Cerebral Palsy Alliance, The University of Sydney
  • CIE Associate Professor Michael Fahey,  Monash Medical Centre
  • CIF Professor Stephen Rose,  Commonwealth Scientific and Industrial Research Organisation (CSIRO)
  • CIG Professor Paul Colditz,  Director of Perinatal Research, The University of Queensland
  • CIH Professor Jenny Ziviani, Professor of Allied health, The University of Queensland
  • CII Associate Professor Catherine Elliott, Curtin University of Technology
  • CIJ Professor Ngaire Stott, The University of Auckland, New Zealand

Learn more about Our People

The AusCP-CTN CRE will function via three main networks: Researchers, Clinicians and Consumers (people with Cerebral Palsy and their families).  The AusCP-CTN CRE includes an array of research across five themes:

  1. Pre-clinical and Neuroprotection
  2. Early Detection and Neuroimaging
  3. Clinical Trials
  4. Knowledge Translation and Implementation
  5. Engagement, Health Policy, Education & Training

 

Learn more about Our Research

Our Mission

The CRE for the Australasian CP Clinical Trials Network will:

1. Uplift earlier detection of CP.

2. Fast-track children to multisite randomised clinical trials of new neuroprotectants.

3. Develop and test new rehabilitation methods.

4. Ensure new knowledge is transferred effectively to enhance clinical practice by overcoming known barriers to implementation.

5. Develop international clinical practice guidelines guided by a consumer network.